コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 detection of Alzheimer's disease (AD) at the preclinical stage.
2 o subtle memory deficits observed during the preclinical stage.
3 or drug absorption and metabolism during the preclinical stage.
4 ected longitudinal changes, including at the preclinical stage.
5 ility of virus acquisition by insects at the preclinical stage.
6 indicate increased ADRD vulnerability at the preclinical stage.
7 ation of the development of new drugs in the preclinical stage.
8 pes in AD pathophysiology, starting from the preclinical stage.
9 een infants developing LOS and controls in a preclinical stage.
10 asis on the need for scientific rigor in the preclinical stage.
11 mitochondrial disorders are now at a mature preclinical stage.
12 ) PIB binding was observed during this early preclinical stage.
13 currently in clinical use or at the advanced preclinical stage.
14 ials have begun to target individuals at the preclinical stage.
15 d with metabolic disturbances already at the preclinical stage.
16 re cognitive symptoms emerge-during the long preclinical stage.
17 st clinical episode and, importantly, at the preclinical stage.
18 harbinger of Alzheimer disease (AD), even in preclinical stages.
19 lecular signature that emerges in very early preclinical stages.
20 ation of future disease was evaluated across preclinical stages.
21 ely phagocytose prions or PrPSc during early preclinical stages.
22 duals with early impaired kidney function at preclinical stages.
23 identify persons "at high risk" of AD in the preclinical stages.
24 sive due to rapid progression and absence of preclinical stages.
25 ndeed evaluating treatments at prodromal and preclinical stages.
26 le the survey of vascular pathologies during preclinical stages.
27 aptic dysfunction can be imaged beginning at preclinical stages.
28 anifestations of CTE, including clinical and preclinical stages.
29 hippocampal atrophy differ based on initial preclinical staging.
30 biomarkers, individuals were classified into preclinical stage 0 (Abeta-/ND-), 1 (Abeta+/ND-), or 2+
32 derate dementia from AD (AD(2)) and at their preclinical stage 3 to 8 yr earlier (AD(1)), with no dif
33 y are to evaluate the rate of progression of preclinical (Stage A and B) heart failure, identify asso
35 nt, fully penetrant retinal dystrophy with a preclinical stage, an onset after the age of 30 years, a
36 ncreases in the whole AD continuum since the preclinical stage and represents a promising biomarker o
37 preselection and evaluation of drugs at the preclinical stage and the testing of putative neuroprote
38 rk deterioration on memory impairment in the preclinical stage, and a biphasic influence of the angul
39 tial dysbiosis in high-risk individuals at a preclinical stage, and therapeutically target pathogenic
40 ies are being developed and evaluated at the preclinical stage, and will lead to clinical trials in t
41 nt without metabolic consequences until late preclinical stages,and it remains unknown how early in t
43 but can emerge earlier in prodromal and even preclinical stages as part of mild behavioural impairmen
45 c co glycolic acid (PLGA) was chosen in this preclinical stage because it is readily translatable to
47 s, especially if they can be identified in a preclinical stage by the development of antecedent bioma
48 in early childhood, can be identified in the preclinical stages by the detection of catecholamines in
50 arly detection of brain abnormalities at the preclinical stage can be useful for developing preventiv
53 liest solid tumor, is still incurable in the preclinical stages due to multifacet stroma, dense desmo
55 omise for precise diagnostics, especially at preclinical stages, facilitating personalized patient ma
57 and mitigation of immunogenicity risk at the preclinical stage has the potential to reduce the incide
58 n insulin-resistant individuals at an early, preclinical stage, ie, well before the development of gl
59 g autoaggressive process beneficially at the preclinical stage, if produced at the correct location,
60 ary age-related tauopathy, likely already in preclinical stages in individuals with low Abeta patholo
61 nuclear antigen reactivity particularly, at preclinical stages/in at-risk subjects could be predicti
62 ibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antivir
63 understanding of these relationships in the preclinical stage may advance our mechanistic understand
66 ication, for identifying participants at the preclinical stage of AD who may be at risk for cognitive
69 med that plasma p-tau181 is increased at the preclinical stage of Alzheimer and further increases in
70 major growth in Abeta burden occurs during a preclinical stage of Alzheimer disease (AD), prior to th
72 appears at the prodromal and possibly at the preclinical stage of Alzheimer's disease, and seems to p
78 e estimates for clinical trials aimed at the preclinical stage of the disorder (HCs with evidence of
79 thus may provide protection against Abeta in preclinical stages of AD and other neurodegenerative pro
80 Conclusions and Relevance: More advanced preclinical stages of AD have greater longitudinal Abeta
81 fted to targeting at-risk populations in the preclinical stages of AD thus improved predictive marker
82 au217 levels were increased during the early preclinical stages of AD when insoluble tau aggregates w
89 which the hippocampus becomes hyperactive in preclinical stages of Alzheimer's disease (AD) have thus
90 efects and axonopathy are prominent in early preclinical stages of Alzheimer's disease (AD), often pr
91 -inositol and other metabolites occur in the preclinical stages of Alzheimer's disease associated wit
92 gm can detect metabolic abnormalities in the preclinical stages of Alzheimer's disease despite normal
93 sponse to amyloid-related neuronal injury in preclinical stages of Alzheimer's disease, but is relate
97 comorbidities and their risk factors in the preclinical stages of chronic obstructive pulmonary dise
98 comorbid diseases were more prevalent in the preclinical stages of COPD and smokers without COPD.
102 use models of RA and investigations into the preclinical stages of disease also support the hypothesi
103 trullinated protein antibodies (ACPA) during preclinical stages of disease and accumulation of hyperc
106 NOD female mice representing early and late preclinical stages of disease were treated with mouse an
107 ent in pyramidal neurons of the neocortex at preclinical stages of disease when Alzheimer-like neurop
110 hnology can have critical roles in different preclinical stages of drug development and highlight the
111 alternative guide for drug therapy at early, preclinical stages of graft rejection and for evaluating
114 eviously found to contribute to the earliest preclinical stages of pancreatic beta cell destruction.
116 shift in functional microglial phenotypes in preclinical stages of superoxide dismutase 1 (SOD1)-muta
118 fective, this therapy should be given in the preclinical stages of the disease, which are assessed mo
119 hypertension, but its role as a biomarker of preclinical stages of this disease has not been investig
120 velopment may permit recognition of early or preclinical stages of vascular contributions to cognitiv
121 s the field begins to test the concept of a "preclinical" stage of neurodegenerative disease, when th
122 ly detection of autoimmunity, potentially at preclinical stages, offers a window of opportunity for t
123 cal and neuropathological changes during the preclinical stages (onset approximately 24-30 months of
124 beta and their receptors was examined at the preclinical stage, onset, peak, and recovery by RT-PCR a
125 nt of multiple ZIKV vaccines that are at the preclinical stage or in early-stage clinical trials.
126 We found that these cells are sensitive to preclinical stage pharmacological inhibitors of N-myrist
127 s the brain's functional architecture in the preclinical stage, possibly contributing to pathology pr
128 lzheimer disease (AD) pathophysiology at the preclinical stage, prior to the onset of mild cognitive
129 larger cardiac tissue constructs remains in preclinical stages, progress has been achieved in the de
130 e show that (a) sera from FS patients in the preclinical stage recognized epitopes on the COOH-termin
135 ished to give developers of new drugs in the preclinical stage the opportunity to test the metabolism
136 mined cross-sectional associations across AD preclinical stages, those with all biomarkers normal, an
137 drug development pipeline, from 2.0% at the preclinical stage to 8.2% among mechanisms for approved
138 biological continuum, from its asymptomatic preclinical stage to its clinically overt dementia stage
139 anslating these promising therapies from the preclinical stage to the clinic, especially for genome e
140 urred in microglial activity during the late preclinical stage, transitioning from PrPSc uptake to es
141 icancer activity are often developed through preclinical stages using response criteria observed in c
142 stand their relationship during the earliest preclinical stages, we investigated baseline CSF markers
145 to market involves many steps, including the preclinical stage, where various properties of the drug
146 of immediate free recall/new learning at the preclinical stage, which is mediated by progressive atro
147 romote specific CD4+ T-cell responses in the preclinical stage, while in MCI it may be important to t
148 novel antigens, adjuvants and vectors in the preclinical stage with computational analyses of clinica
149 ed by UAAs impact the progress of analogs in preclinical stages with an emphasis on the role played b